Exosomes as a biomarker platform for detecting epidermal growth factor receptor-positive high-grade gliomas

OBJECTIVE High-grade glial brain tumors are often characterized by an elevated expression of the tumorigenic epidermal growth factor receptor variant III ( EGFRvIII). The authors sought to establish a clinically adaptive protocol as a noninvasive diagnostic tool for EGFRvIII detection through serum...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Journal of neurosurgery Ročník 128; číslo 4; s. 1091
Hlavní autoři: Manda, Sasidhar Venkata, Kataria, Yogesh, Tatireddy, Babul Reddy, Ramakrishnan, Balasubramaniam, Ratnam, Boola Gnana, Lath, Rahul, Ranjan, Alok, Ray, Amitava
Médium: Journal Article
Jazyk:angličtina
Vydáno: United States 01.04.2018
Témata:
TCGA = The Cancer Genome Atlas
circulatory biomarkers
GBM = glioblastoma
oncology
EGFRvIII = epidermal growth factor receptor variant III
OS = overall survival
PPV = positive predictive value
exosomes
NPV = negative predictive value
TEM = transmission electron microscopy
EGFRvIII
RT = reverse transcription
GAPDH = glyceraldehyde 3-phosphate dehydrogenase
EGFR = epidermal growth factor receptor
liquid biopsy
PCR = polymerase chain reaction
ISSN:1933-0693, 1933-0693
On-line přístup:Zjistit podrobnosti o přístupu
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
Popis
Shrnutí:OBJECTIVE High-grade glial brain tumors are often characterized by an elevated expression of the tumorigenic epidermal growth factor receptor variant III ( EGFRvIII). The authors sought to establish a clinically adaptive protocol as a noninvasive diagnostic tool for EGFRvIII detection through serum exosomes. METHODS Purity of serum exosome/RNA was confirmed by electron microscopy and flow cytometry and through an RNA bioanalyzer profile. EGFRvIII amplification was initially established by semiquantitative polymerase chain reaction in tumor tissues and exosomes. Diagnostic performance of EGFRvIII transcript in tissue versus exosome was determined using a 2 × 2 clinical table approach. Overall survival was determined using Kaplan-Meier analysis. RESULTS The EGFRvIII transcript was detected in 39.5% of tumor tissue samples and in 44.7% of their paired serum exosome samples; 28.1% of biopsy tumors coexpressed wild-type EGFR and EGFRvIII. Tissue EGFRvIII amplification served as the reference-positive control for its paired serum expression. The overall clinical sensitivity and specificity of semiquantitative exosome EGFRvIII polymerase chain reaction detection assay in serum were 81.58% (95% CI 65.67%-92.26%) and 79.31% (95% CI 66.65%-88.83%), respectively. Age, sex, tumor location, and side of the body on which the tumor was located had no effect on the detection rate of exosomal EGFRvIII transcript. EGFRvIII expression either in exosomes or tissue correlated with poor survival. CONCLUSIONS The authors established a serum-based method for detection of EGFRvIII in high-grade brain tumors that might serve as an optimal noninvasive method for diagnosing EGFRvIII-positive high-grade gliomas.
Bibliografie:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:1933-0693
1933-0693
DOI:10.3171/2016.11.JNS161187